SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community members discuss recent price movements and potential future rallies, with some eyeing the $130 and $200 price range. Bullish sentiment is fueled by discussions of short squeezes and historical patterns, while others remain skeptical, pointing to LTC's past underperformance relative to other cryptocurrencies. Overall, the conversation revolves around whether Litecoin can sustain its current momentum amid broader market trends.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as the community rallies around its real-world applications, from KENDU Energy to KENDU Unleashed skateboards, and the upcoming KENDU Games release on Steam. The community is actively discussing the best ways to "KENDU" everything, from real-life products to in-game integrations, reinforcing their belief in the long-term vision of the project. Holders are sharing bullish sentiments and celebrating the consistent building and marketing efforts of the project.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group ($UNH) is trending amidst concerns about potential impacts from government actions related to healthcare subsidies and the ACA. Community discussions revolve around whether Trump's proposals to redirect funds will hurt or help the company, with some arguing it could devastate smaller insurers and leave UNH as the only one standing. Investors are also closely watching for news on government shutdowns, potential impacts on earnings, and upcoming disclosures from major holders like Warren Buffett.

Dow, Inc. is a materials science company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes and construction chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dow Inc. is trending as the community discusses the impact of a dividend cut and lowered price targets, with some seeing the drop as an overreaction and potential buying opportunity. Investors are weighing the impact of trade and tariff uncertainties on the cyclical chemical company, while monitoring key support levels and waiting for a potential turnaround. Attractive dividend yields of competitors like $HUN are also being discussed.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Exact Sciences Corp.

EXAS is trending amid discussions about its competitive positioning and potential catalysts, particularly related to upcoming earnings and product launches. Community members are weighing the impact of new products like Cancerguard against existing competition and evaluating the company's growth prospects. Recent analyst ratings and target price adjustments are also fueling the conversation around the stock's valuation.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik ($RBRK) is trending amid discussions about its recent price action following earnings, with some investors viewing the dip as a buying opportunity and citing the company's growth potential in the cybersecurity and AI sectors. Community members are debating whether the stock is currently overvalued and some suggest potential acquisition by Crowdstrike ($CRWD). Several analysts have reiterated or upgraded their price targets, while others express frustration with the stock's performance.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is trending due to positive sentiment surrounding its RNAi platform and potential S&P 500 inclusion. Community discussions highlight the company's valuation, recent analyst target price increases, and actionable options trade alerts. Additionally, Alnylam's innovative approach in the biotech sector and potential as a retail squeeze candidate are sparking interest.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

LENZ is trending amid discussions about a potential FDA catalyst related to its VIZZ treatment, with community members weighing in on its market potential and adoption. Some are highlighting recent insider buying and institutional interest, while others debate the impact of short positions and potential acquisitions. Community members are also analyzing script data and revenue projections.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending due to market speculation surrounding its bidding war with Pfizer for Metsera, with community chatter focusing on the potential impact of winning or losing the deal and what it signals for NVO's pipeline and strategic direction; some traders believe NVO may be overpaying for the asset. Investors are also closely watching upcoming FDA decisions on oral treatments and potential price adjustments amid broader discussions on access to weight-loss drugs.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential and recent price action, with some speculating about a run to new highs. The focus is on ICP's technology and real-world utility, particularly with its integration of AI through Caffeine AI. Discussions also highlight the possibility of increased adoption and potential listings on major exchanges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 16,575 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Kenneth Bate sold 16,575 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 5th...

FY2025 Earnings Estimate for MDGL Issued By B. Riley

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - B. Riley decreased their FY2025 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a report released on Tuesday, November...

What is HC Wainwright's Estimate for MDGL FY2025 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at HC Wainwright lowered their FY2025 EPS estimates for Madrigal Pharmaceuticals in a report released on Wednesday, November 5th...

Cantor Fitzgerald Brokers Reduce Earnings Estimates for MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Madrigal...

Equities Analysts Offer Predictions for MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report released on...

What is B. Riley's Estimate for MDGL Q4 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Research analysts at B. Riley issued their Q4 2026 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a research...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $527.00 at Citizens Jmp

Citizens Jmp lifted their price target on Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a "market outperform" rating in a report on Wednesday...

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of -156.57% and +15.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for

electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$491.31
Prev Close	$488.58
Open	$488.03
Dividend Yield	0.00%
50-Day Moving Average	$437.14
Beta	0.80
Avg. Volume	282,629.74
PE Ratio	-37.61

52-Week High	$496.98
52-Week Low	$265.00
Market Capitalization	$11.11B
EPS (Annual)	-$21.90
Price to Book	17.75
Revenue Per Employee	$341,160.98
Enterprise Value/EBITDA	N/A

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc